Citi analyst Stephanie Demko raised her price target for Tabula Rasa HealthCare to $76 saying the company saw continued momentum with a “strong” Q2 beat. The conference call highlighted multiple new initiatives, including expansion into the clinician market and Western Europe, Demko tells investors in a post-earnings research note. She believes Tabula has multiple “shots on goal” to accelerate out-year growth and keeps a Buy rating on the name.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.